Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Feature

Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

Posted on: 03 Feb 04
Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

Summary

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.

Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function


May 17-18, 2004


The Westin Princeton at Forrestal Village


 


About this Conference


 


Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Leading researchers will share findings obtained from animal models and clinical studies in which drugs have been targeted to cholinergic, glutamatergic, GABAergic, histaminergic, and specific second messenger pathways, as well as KCNQ potassium channels. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.


 


Among the cutting-edge presentations you’ll hear are:


 


*Exploring the PDE-4/CREB Pathway


Tim Tully, Helicon Therapeutics


 


*GABA-B antagonists: Preclinical and Clinical Profile of SGS742, a novel GABA-B receptor antagonist


Thorsten Melcher, Saegis Pharmaceuticals, Inc.


 


*AMPA Receptor Modulation


Gary Rogers, Cortex Pharmaceuticals


 


*H3 Antagonists: Broad Preclinical Efficacy in Cognition and Schizophrenia


Gerard Fox, Abbott Laboratories


 


*TC-1734: An Orally Active Neuronal Nicotinic Receptor Modulator and Long-Lasting Cognitive Enhancing Properties and Neuroprotective Properties


Gregory Gatto, Targacept, Inc.


 


*KCNQ Channels as Potential Targets for the Treatments of Cognitive Diseases


William Dalby Brown, Neurosearch A/S (Denmark)


 


*M1 Muscarinic Agonists: Their Therapeutic Potential in Alzheimer’s Disease (AD) and Related Diseases


Abraham Fisher, Israel Institute for Biological Research, Ness Ziona, Israel


 



PLUS: A Special Workshop: Overcoming the Blood Brain Barrier in CNS Drug Delivery”


Part I: The Blood-brain Barrier and Delivery of Drug and Gene Therapeutics to the CNS


Part II: Intranasal Drug Delivery to the CNS


 


Presenter, Parts I and II : William H. Frey, II, Alzheimer’s Research Center, Regions Hospital and University of Minnesota


 


Part III: Peptide Transport Across the Blood-Brain Barrier


Weihong Pan, Tulane University and VA Medical Center


 


This event is truly a must-attend chance to hear the latest research in the rapidly growing field of cognitive enhancing drugs.


 


To register, call 800-686-2276 or click to register here http://www.pharmedassociates.com/rand.asp#p166

Jennifer McGinnis

Last updated on: 27/08/2010 11:40:18

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.